Thursday, September 5

4:25 – 4:45 pm

Paper Presentation: Education Across the Cancer Care Continuum — Creating a Practical End-of-Life Care Mini-Workshop (204-3)

Fortunately, there have been great strides in the progress of treating children diagnosed with cancer during the last 50 years, with ever-increasing survivor outcomes. This is what every practitioner working in the pediatric oncology field strives and hopes for. And yet, despite the remarkable and increasingly sophisticated treatment options, not all children will survive their diagnosis with cancer. In general, nurses have more training, education, and skills with delivering chemotherapy, biotherapy, and other interventions than in providing end-of-life care.

Speaker:
Leslie Griffith, BSN MA CPHON®
CNE Hours
0.33
5:00–6:00 pm

Symptom Assessment and Associated Biomarkers (206)

Altered sleep and increased fatigue are reported as two of the most distressing symptoms during treatment and into survivorship. Prevalence of disrupted sleep and fatigue have been reported to be higher among patients treated for CNS tumors, those treated with radiation therapy, solid tumors, and Hodgkin Lymphoma; however, changes in sleep and fatigue have been reported across all cancer diagnoses. To elucidate the biological mechanism underlying these symptoms, symptom science has evolved from descriptive studies of symptom occurrence to the measurement of biological processes.

5:00–6:00 pm

Non-Pharmacologic Treatment of Pain in Sickle Cell Disease (207)

Sickle cell disease (SCD) is characterized by episodes of severe and unpredictable pain that requires adaptation to remain healthy and functional. A more holistic view of pain assessment and treatment is necessary to address the bio-psychosocial needs of the individual in or at risk for pain. The treatment of SCD should include all available modalities to enhance the disease process, pain management, and psychosocial functioning.

Speaker:
Megan Coco, MSN RN CPNP-PC
CNE Hours
1
5:00–6:00 pm

Decoding the Mystery of Gene Therapy – An Overview for Nursing (208)

The decoding of the human genome has provided scientists and researchers a new pathway to developing potential curative therapies for life-threatening or otherwise fatal illnesses. The development of these gene therapies is moving at lightning speed, translating this novel therapy from the bench to the bedside at a record pace. What was once thought of as a highly experimental approach, these therapies are quickly becoming standard of care, as demonstrated by the recent Food and Drug Administration (FDA) approval of several gene therapies, specifically Chimeric Antigen Receptor (CAR) T cell for B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma. These therapies are complex both in their scientific development and, more importantly, in their clinical delivery.

Speaker:
Colleen Dansereau, MSN RN CPN
CNE Hours
1